Estetrol/Drospirenone to Reduce the Average Size of Endometriomas — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas — Stella

Recruiting

Back to Ovarian Endometrioma trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Canada

McGill University Health Center, Montreal, Quebec

Key details

Phase

Post-approval study

Sponsor

Andrew Zakhari

Enrollment target

~21 participants

Started

December 2024

Primary completion

November 2026

Age range

18 Years and older

Sex

Female only

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov